Effect of Cabergoline on Weight and Glucose Tolerance

This study has been completed.
Information provided by (Responsible Party):
Judith Korner, Columbia University
ClinicalTrials.gov Identifier:
First received: July 14, 2011
Last updated: October 13, 2015
Last verified: October 2015

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Condition Intervention Phase
Body Weight
Impaired Glucose Tolerance in Obese
Drug: Cabergoline
Other: placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • body weight [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • glucose [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: April 2002
Study Completion Date: July 2011
Primary Completion Date: September 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
placebo pill
Other: placebo
1 pill twice weekly
Active Comparator: cabergoline
cabergoline pill
Drug: Cabergoline
cabergoline 0.5 mg twice weekly


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 18 - 55 years
  • BMI 30 -40

Exclusion Criteria:

  • diabetes,
  • clinically significant medical condition,
  • use of medications that effect blood glucose or body weight
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01395602

United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Principal Investigator: Judith Korner, MD, PHD Columbia University
  More Information

Responsible Party: Judith Korner, Associate Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT01395602     History of Changes
Other Study ID Numbers: IRB #13952 
Study First Received: July 14, 2011
Last Updated: October 13, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Body Weight
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Signs and Symptoms
Anti-Dyskinesia Agents
Antineoplastic Agents
Antiparkinson Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 25, 2016